{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:42:27Z","timestamp":1790804547658,"version":"4.1.0"},"reference-count":64,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Marche Biobank Project","award":["POR FESR 2014\u20132020"],"award-info":[{"award-number":["POR FESR 2014\u20132020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Systemic sclerosis, also known as scleroderma or SSc, is a condition characterized by significant heterogeneity in clinical presentation, disease progression, and response to treatment. Consequently, the design of clinical trials to successfully identify effective therapeutic interventions poses a major challenge. Recent advancements in skin molecular profiling technologies and stratification techniques have enabled the identification of patient subgroups that may be relevant for personalized treatment approaches. This narrative review aims at providing an overview of the current status of skin gene expression analysis using computational biology approaches and highlights the benefits of stratifying patients upon their skin gene signatures. Such stratification has the potential to lead toward a precision medicine approach in the management of SSc.<\/jats:p>","DOI":"10.3390\/ijms241612548","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T12:26:39Z","timestamp":1691497599000},"page":"12548","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9867-2360","authenticated-orcid":false,"given":"Devis","family":"Benfaremo","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-6325","authenticated-orcid":false,"given":"Silvia","family":"Agarbati","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-8446","authenticated-orcid":false,"given":"Matteo","family":"Mozzicafreddo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-7408","authenticated-orcid":false,"given":"Chiara","family":"Paolini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Svegliati","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Moroncini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy"},{"name":"Clinica Medica, Department of Internal Medicine, Marche University Hospital, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iii14","DOI":"10.1093\/rheumatology\/kep108","article-title":"Skin disease: A cardinal feature of systemic sclerosis","volume":"48","author":"Krieg","year":"2009","journal-title":"Rheumatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: A study of the prospective EUSTAR cohort","volume":"4","author":"Elhai","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fmed.2017.00120","article-title":"Pathophysiological Mechanisms in Sclerosing Skin Diseases","volume":"4","author":"Eckes","year":"2017","journal-title":"Front. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_5","unstructured":"Hachulla, E., Mihai, C., and Bruni, C. (2019). EULAR Textbook on Systemic Sclerosis, BMJ Publishing. [2nd ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Matucci-Cerinic, M., and Denton, C.P. (2019). Atlas of Ulcers in Systemic Sclerosis: Diagnosis and Management, Springer International Publishing.","DOI":"10.1007\/978-3-319-98477-3"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102458","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud\u2019s phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_8","first-page":"104","article-title":"OP0065 The very early diagnosis of systemic sclerosis (vedoss) project: Predictors to develop definite disease from an international multicentre study","volume":"78","author":"Randone","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","first-page":"34","article-title":"Management of digital ulcers in patients with systemic sclerosis","volume":"137","author":"Riemekasten","year":"2012","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/acr.22672","article-title":"Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro-Osteolysis in Systemic Sclerosis","volume":"68","author":"Morardet","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/03007995.2021.1992371","article-title":"How do systemic sclerosis manifestations influence patients\u2019 lives? Results from a survey on patients and caregivers","volume":"37","author":"Galetti","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103314","DOI":"10.1016\/j.autrev.2023.103314","article-title":"Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians","volume":"22","author":"Keret","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(16)00578-X","article-title":"Acute respiratory distress syndrome","volume":"388","author":"Sweeney","year":"2016","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41591-022-01880-6","article-title":"The promise of precision medicine in rheumatology","volume":"28","author":"Guthridge","year":"2022","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eabn4776","DOI":"10.1126\/sciadv.abn4776","article-title":"Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases","volume":"8","author":"Martinez","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/rheumatology\/keac344","article-title":"A Genomic Meta-Analysis of Clinical Variables and Their Association with Intrinsic Molecular Subsets in Systemic Sclerosis","volume":"62","author":"Franks","year":"2022","journal-title":"Rheumatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/annrheumdis-2021-219884","article-title":"Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes","volume":"80","author":"Kerick","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1038\/s41467-019-12760-y","article-title":"GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways","volume":"10","author":"Kerick","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Milano, A., Pendergrass, S.A., Sargent, J.L., George, L.K., McCalmont, T.H., Connolly, M.K., and Whitfield, M.L. (2008). Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE, 3.","DOI":"10.1371\/annotation\/05bed72c-c6f6-4685-a732-02c78e5f66c2"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/jid.2011.472","article-title":"Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies","volume":"132","author":"Pendergrass","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2020-217840","article-title":"Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement","volume":"80","author":"Showalter","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2018-214778","article-title":"Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis","volume":"78","author":"Moon","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Johnson, Z.I., Jones, J.D., Mukherjee, A., Ren, D., Feghali-Bostwick, C., Conley, Y.P., and Yates, C.C. (2018). Novel classification for global gene signature model for predicting severity of systemic sclerosis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199314"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/art.40898","article-title":"A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets","volume":"71","author":"Franks","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00281-015-0509-1","article-title":"The role of the acquired immune response in systemic sclerosis","volume":"37","author":"Chizzolini","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/art.41758","article-title":"Transcriptomic Evaluation of Juvenile Localized Scleroderma Skin with Histologic and Clinical Correlation","volume":"73","author":"Schutt","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00281-015-0512-6","article-title":"Gene expression profiling offers insights into the role of innate immune signaling in SSc","volume":"37","author":"Johnson","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mahoney, J.M., Taroni, J., Martyanov, V., Wood, T.A., Greene, C.S., Pioli, P.A., Hinchcliff, M.E., and Whitfield, M.L. (2015). Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms. PLoS Comput. Biol., 11.","DOI":"10.1371\/journal.pcbi.1004005"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-018-0099-0","article-title":"New insights into the genetics and epigenetics of systemic sclerosis","volume":"14","author":"Angiolilli","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Werner, G., Sanyal, A., Mirizio, E., Hutchins, T., Tabib, T., Lafyatis, R., Jacobe, H., and Torok, K.S. (2023). Single-Cell Transcriptome Analysis Identifies Subclusters with Inflammatory Fibroblast Responses in Localized Scleroderma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24129796"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chitturi, P., Xu, S., Ahmed Abdi, B., Nguyen, J., Carter, D.E., Sinha, S., Arora, R., Biernaskie, J., Stratton, R.J., and Leask, A. (2023). Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis. Ann. Rheum. Dis.","DOI":"10.1136\/ard-2023-223859"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","article-title":"Extracellular matrix structure","volume":"97","author":"Theocharis","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3748\/wjg.v13.i22.3056","article-title":"Transforming growth factor-beta and fibrosis","volume":"13","author":"Verrecchia","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7113-8_1","article-title":"Human Fibrotic Diseases: Current Challenges in Fibrosis Research","volume":"1627","author":"Rosenbloom","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Karatzas, E., Kakouri, A.C., Kolios, G., Delis, A., and Spyrou, G.M. (2021). Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0249687"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kim, Y.A., Wuchty, S., and Przytycka, T.M. (2011). Identifying causal genes and dysregulated pathways in complex diseases. PLoS Comput. Biol., 7.","DOI":"10.1371\/journal.pcbi.1001095"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e89073","DOI":"10.1172\/jci.insight.89073","article-title":"Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity","volume":"1","author":"Lofgren","year":"2016","journal-title":"JCI Insight"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bhattacharyya, S., Sargent, J.L., Du, P., Lin, S., Tourtellotte, W.G., Takehara, K., Whitfield, M.L., and Varga, J. (2011). Egr-1 induces a profibrotic injury\/repair gene program associated with systemic sclerosis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023082"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Assassi, S., Radstake, T.R., Mayes, M.D., and Martin, J. (2013). Genetics of scleroderma: Implications for personalized medicine?. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-9"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1186\/1755-1536-5-S1-S19","article-title":"Molecular targets for therapy in systemic sclerosis","volume":"5","author":"Iwamoto","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1186\/1755-1536-5-S1-S24","article-title":"CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis","volume":"5","author":"Lipson","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2021-221352","article-title":"Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time","volume":"81","author":"Skaug","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/art.40455","article-title":"Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis","volume":"70","author":"Stifano","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/jid.2013.130","article-title":"Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis","volume":"133","author":"Hinchcliff","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","article-title":"Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin","volume":"138","author":"Hinchcliff","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/art.24221","article-title":"Molecular framework for response to imatinib mesylate in systemic sclerosis","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: An open-label, pilot clinical trial","volume":"17","author":"Gordon","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Paolini, C., Agarbati, S., Benfaremo, D., Mozzicafreddo, M., Svegliati, S., and Moroncini, G. (2022). PDGF\/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073904"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: Insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e159566","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/annrheumdis-2015-208154","article-title":"Influence of TYK2 in systemic sclerosis susceptibility: A new locus in the IL-12 pathway","volume":"75","author":"Guerra","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Fukasawa, T., Yoshizaki-Ogawa, A., Yoshizaki, A., and Sato, S. (2023). Impact of guselkumab on three cases of SSc accompanying psoriasis. Rheumatology.","DOI":"10.1093\/rheumatology\/kead287"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2023.02.061","article-title":"Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial","volume":"89","author":"Fukasawa","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lescoat, A., Huang, S., Carreira, P.E., Siegert, E., de Vries-Bouwstra, J., Distler, J.H.W., Smith, V., Del Galdo, F., Anic, B., and Damjanov, N. (2023). Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database. JAMA Dermatol.","DOI":"10.1001\/jamadermatol.2023.1729"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/12548\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:27:48Z","timestamp":1760128068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/16\/12548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":64,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["ijms241612548"],"URL":"https:\/\/doi.org\/10.3390\/ijms241612548","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]}}}